Amphastar Pharmaceuticals (AMPH) Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AMPH shares.
View AMPH analyst ratings or view top-rated stocks.

2 brokerages have issued 1 year target prices for Amphastar Pharmaceuticals' shares. Their AMPH share price forecasts range from $70.00 to $71.00. On average, they expect the company's stock price to reach $70.50 in the next year. This suggests a possible upside of 54.9% from the stock's current price.
View analysts price targets for AMPH or view top-rated stocks among Wall Street analysts.

Amphastar Pharmaceuticals' stock was trading at $28.02 at the start of the year. Since then, AMPH shares have increased by 62.4% and is now trading at $45.51.
View the best growth stocks for 2023 here.

Amphastar Pharmaceuticals saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 1,300,000 shares, a decrease of 12.8% from the August 15th total of 1,490,000 shares. Based on an average daily trading volume, of 439,100 shares, the short-interest ratio is presently 3.0 days. Approximately 3.6% of the shares of the stock are short sold.
View Amphastar Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our AMPH earnings forecast.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) released its quarterly earnings results on Tuesday, August, 8th. The company reported $0.58 EPS for the quarter, topping the consensus estimate of $0.52 by $0.06. The firm earned $145.71 million during the quarter, compared to analysts' expectations of $137.20 million. Amphastar Pharmaceuticals had a trailing twelve-month return on equity of 20.12% and a net margin of 18.85%.

ETFs with the largest weight of Amphastar Pharmaceuticals (NASDAQ:AMPH) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Innovator IBD 50 ETF (FFTY), Janus Henderson Small Cap Growth Alpha ETF (JSML), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), ETC 6 Meridian Small Cap Equity ETF (SIXS), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and ERShares NextGen Entrepreneurs ETF (ERSX).

35 employees have rated Amphastar Pharmaceuticals Chief Executive Officer Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among the company's employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Amphastar Pharmaceuticals to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT).

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

Amphastar Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (12.61%), Dimensional Fund Advisors LP (4.00%), State Street Corp (2.85%), Geode Capital Management LLC (1.62%), Northern Trust Corp (1.32%) and Granite Investment Partners LLC (1.10%). Insiders that own company stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters, William J Peters and Yakob Liawatidewi.
View institutional ownership trends.

Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMPH stock can currently be purchased for approximately $45.51.

Amphastar Pharmaceuticals (NASDAQ:AMPH) has a market capitalization of $2.20 billion and generates $498.99 million in revenue each year. The company earns $91.39 million in net income (profit) each year or $1.95 on an earnings per share basis.

The company employs 1,615 workers across the globe.

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The official website for the company is www.amphastar.com. The company can be reached via phone at (909) 980-9484, via email at jasons@amphastar.com, or via fax at 909-980-8296.